A quiet battle is escalating between the Department of Justice and New York’s Attorney General, Letitia James, centered on the medical care of transgender youth. The core of the dispute: NYU Langone Health’s decision to halt certain gender-affirming treatments for minors, a move James vehemently opposes.
The DOJ, through Deputy Attorney General Todd Blanche, has issued a stark warning to James, urging her to withdraw her challenge to NYU Langone’s policy. The federal government argues that federal law doesn’t mandate the hospital to provide these specific treatments, effectively drawing a line in the sand over state versus federal authority in healthcare decisions.
James recently threatened “further action” against the Manhattan hospital, claiming its policy violated state anti-discrimination laws. However, Blanche countered that the hospital’s decision doesn’t constitute discrimination, as the law doesn’t apply to this particular medical program.
NYU Langone’s decision stemmed from a confluence of factors, including the departure of its medical director and mounting pressure from the federal government regarding potential funding repercussions. The hospital maintains its commitment to patient care during this transition, emphasizing that pediatric mental health services will continue uninterrupted.
The Attorney General initially demanded NYU Langone reinstate the program within ten days, asserting no change in federal law justified halting “medically necessary transgender healthcare.” The program in question included hormone therapy, such as puberty blockers, for young patients.
The DOJ’s position is bolstered by a recent Supreme Court ruling, *United States v. Skrmetti*, which upheld Tennessee’s restrictions on certain transgender medical care for minors. This ruling, according to Blanche, supports the idea that NYU Langone’s policy focuses on diagnosis, not gender identity itself.
Crucially, the hospital has confirmed it doesn’t offer “sex-rejecting procedures” to minors. The DOJ argues that because the hospital allows access to puberty blockers and hormones for conditions *other* than gender dysphoria, it avoids a direct conflict with the Supreme Court’s guidance on the relationship between transgender status and medical diagnoses.
The situation remains tense, with the DOJ prepared to defend NYU Langone in court should James pursue legal action. This looming legal battle promises to further ignite the national debate surrounding transgender healthcare and the rights of both patients and medical institutions.
The Attorney General’s office has been contacted for comment, but the core issue remains: where does the authority lie in determining the scope of medical care for vulnerable youth, and what role should the federal government play in influencing those decisions?
